

**Table S1 Main effects of Dapagliflozin in SLE patients with diabetes**

N	1	2	3	4	5
Age/sex	60/F	33/F	45/F	32/F	55/F
Antidiabetic drugs	Glipizide	Acarbose, IRI	IRI	Acarbose, IRI	IRI
eGFR baseline	102.49	142.6	77.0	134.1	60.96
eGFR 6 months	96.94	104.7	96.3	143.7	73.70
Proteinuria at baseline (g/24h)	-	2.89	1.89	-	1.7
Proteinuria at 6 months (g/24h)	-	1.45	2.08	-	7.05
HbA1c baseline (%)	6.8	17.9	9.4	7.6	7.6
HbA1c 6 months (%)	6.9	5.6	7.2	6.9	6.9
FBG baseline (mmol/L)	5.71	9.68	6	10.2	10.1
FBG 6 months (mmol/L)	5.84	4.82	5.91	6.97	7.27
SBP baseline (mmHg)	115/71	114 / 87	120/80	124/101	-
SBP 6 months (mmHg)	122/76	142/98	129/90	118/90	-
BMI baseline (kg/m <sup>2</sup> )	25.36	18.29	24.35	21.26	21.48
BMI 6 months (kg/m <sup>2</sup> )	21.91	18.65	23.31	19.84	20.31

IRI, insulin; FBG, fasting blood-glucose; HbA1c, glycosylated hemoglobin; SBP, systolic blood pressure; BMI, body mass index.

